Should atrial fibrillation patients with hypertension as an additional risk factor of the CHA2DS2-VASc score receive oral anticoagulation?

• 来源期刊: 老年心脏病学杂志（英文版）
• 年，卷（期）: 2018,（3）
• 页码范围: 229-234
• 页数: 6页
• 语种: 英文
• DOI: 10.11909/j.issn.1671-5411.2018.03.005

摘要

Hypertension has been found to be increased a risk of stroke in atrial fibrillation (AF).Both the European and U.S.guidelines advocate the use of the CHA2DS2-VASc (congestive heart failure,hypertension,age ＞ 75 years,diabetes mellitus,stroke/transient ischemic attack,vascular disease,age 65-74 years,sex category) scheme for risk stratification.Although vitamin K antagonists is more effective than acetylsalicylic acid at preventing ischaemic stroke,its benefit is offs by an increased haemorrhage risk.The risk of ischemic stroke in patients with AF and a CHA2DS2-VASc score of 1 are considered to be low risk and may be not expected to benefit from anticoagulation therapy.Hypertension carries an increased risk of ischemic stroke,however,it is also a clear risk factor for hemorrhage in AF.Therefore,the optimal antithrombotic management is highlighted in patients with AF with only one risk factor especially hypertension.